Proactive Investors - Run By Investors For Investors

Frontier IP portfolio firm Exscientia unveils collaboration with Roche as it raises US$26mln in funding round

The agreement will involve using Exscientia’s Centaur Chemis AI drug discovery platform to design pre-clinical drug candidates for the Swiss firm in return for up to 67mln Swiss francs in payments and support
Pharmaceuticals
The agreement also contains tiered royalties on the sales of any products developed

Frontier IP Group Plc’s (LON:FIPP) portfolio firm Exscientia has unveiled a drug discovery collaboration with Swiss healthcare firm Roche as it raised US$26mln in a Series B funding round.

The firm, which commercialises university intellectual property, said the agreement between drug designer Exscientia and Roche would involve using Exscientia’s Centaur Chemis artificial intelligence (AI) drug discovery platform to design pre-clinical drug candidates for the Swiss firm in return for up to 67mln Swiss francs (£53.5mln) in upfront payments, research support and milestone payments.

READ: Halma subsidiary begins commercial roll-out of water test which uses Frontier IP’s investee company’s tech

The agreement also contains tiered royalties on the annual net sales of any products that are developed as a result of the collaboration.

Professor Andrew Hopkins, chief executive of Exscientia, said the partnership “demonstrates the value of our AI-driven platform and its potential to deliver high value assets” and that the use of AI in early stage discovery had “the potential to offer transformational benefits in terms of productivity and quality to the generation of new medicines”.

Exscientia had also raised US$26mln in a Series B funding round to help scale up its pipeline and advance programmes toward clinical development.

The funding round included new investors such as Celgene Corp, an American biotech firm, and specialist healthcare investor GT Healthcare Capital Partners.

German drug developer Evotec, an existing investor, also participated.

Neil Crabb, chief executive of Frontier IP, said the announcements “confirm Exscientia's exciting potential” and that the backing of “major companies in the life sciences industry” had strengthened the firm’s belief that Exscientia “will become one of the leading AI-driven drug discovery companies in the world”.

In late-afternoon trading Monday, Frontier IP shares were up 1.2% at 81p.

View full FIPP profile View Profile

Frontier IP Group PLC Timeline

Related Articles

Interviewees
August 07 2018
The offer values Nash at £98.7mln and DBAY already controls 26.1% of Harvey Nash shares
Online payment
June 12 2019
The company's payment services specialise in card-not-present transactions, payments made without face-to-face contact or verification, usually online or via mobile
Investment papers and laptop
May 07 2019
The investment firm focuses on providing consultancy services to universities and other research organisations to help them commercialise any intellectual property arising from their research

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use